For personal use only

Transcription

1 2011 Annual General Meeting December 1, 2011 NASDAQ (UNIS) and ASX (UNS)

2 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management s beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However you should not place undue reliance on any such forward looking statements as these are subject to risks and uncertainties. Please refer to our press releases and our SEC filings for more information regarding the use of forward looking statements. 2

3 Chairman s Welcome Jim Bosnjak OAM NASDAQ (UNIS) and ASX (UNS)

4 The Unilife Board of Directors Alan Shortall Executive Director and CEO since the founding of Unilife in

5 The Unilife Board of Directors Jeff Carter MApp. BFin Non Executive Director since 2006 CFO of Unilife from Chartered accountant with 25 years experience in financial and senior management roles in U.S. and Australia 5

6 The Unilife Board of Directors William Galle Non-Executive Director since 2008 Serves on Compensation and Nominating and Corporate Governance Committees More than 30 years experience in development and implementation of business growth and alternative investment strategies 6

7 The Unilife Board of Directors John Lund, CPA Non-Executive Director since 2009 Chair of Audit Committee Advising publicly listed companies on SEC reporting, M&A, and public accounting audit services since

8 The Unilife Board of Directors Mary Kate Wold, J.D. Non-Executive Director since 2010 Chair of the Strategic Partnerships Committee CEO of Church Pension Fund Group Previously SVP of Finance, Tax and Treasury at Wyeth 8

9 The Unilife Board of Directors Marc Firestone J.D. Non-Executive Director since 2010 Chair of Nominating and Corporate Governance Committee Executive Vide President and General Counsel for Kraft Foods 9

10 Agenda 1. Confirmation of Quorum 2. Resolutions Achievements and Outlook Alan Shortall 4. Questions 5. Confirmation of Results 6. Other Business 10

11 Confirmation of Quorum Unilife s quorum requirement is one-third of outstanding shares being represented either in person or by proxy Unilife has received at least 50% of the total outstanding shares entitled to vote are represented by person or by proxy. 11

12 CEO Presentation by Mr. Alan Shortall NASDAQ (UNIS) and ASX (UNS)

13 Our Position Redefining the market for advanced drug delivery systems Innovative, differentiated devices that can enable, enhance and extend the commercial success of injectable drugs and vaccines A rich portfolio of device technologies driven by unmet needs Our devices address the specific needs of the pharmaceutical customer, the therapeutic drug and the target patient Fully serving our customers with speed, agility and reliability Collaborations can originate during the clinical development of a pipeline drug and span its entire commercial lifecycle 13

14 Annual Highlights State-of-the-art facility in York, PA 14

15 Our Broad Operational Capabilities Enabling us to serve as an integrated partner for device innovation 15

16 Annual Highlights Continued to strengthen world-class team Management appointments this year include: Name Title Previous Employment Dr. Ramin Mojdeh COO BD (Pharma Systems & Product Development) Dr. Jack Kelley VP, Strategic Marketing BD, Medtronic Mike Ratigan VP, Commercial Development BD, Stryker Dr. Masoud Samandi VP, R&D BD Todd Smith VP, Integrated Supply Chain ConvaTec, Bristol Myers Squibb, Accenture Ian Hanson Director, Advanced Delivery Medtronic Diabetes Joe Runkle Senior Scientist Teleflex, West Pharma Alex Goraltchouk Snr Mngr, Advanced Drug Delivery Allergan Dr. Ashley Palmer Mngr, Advanced Drug Delivery BD Dr. Jyoti Gupta Mngr, Advanced Drug Delivery BD Dr. Gautam Shetty Mngr, Advanced Drug Delivery BD Dr. Molly Miller (BD) Mngr, Advanced Drug Delivery BD 16

17 Annual Highlights Completion of Unifill Syringe Industrialization Program 17

18 Annual Highlights Commenced Initial Supply of Unifill Syringe 18

19 Annual Highlights U.S. Rollout of Unitract 1mL syringes 19

20 Annual Highlights Diversified portfolio of Advanced Drug Delivery Systems 20

21 Annual Highlights Unifill Select 21

22 Annual Highlights Rita Auto-Injector 22

23 Annual Highlights AutoInfusor 23

24 Annual Highlights Novel Device for Targeted Organ Delivery First organ delivery device scheduled to enter into drug clinical trials with pharmaceutical partner in early 2012 Strong financial opportunity with U.S. and international prevalence rates for the target disease state being very high U.S. treatment costs exceeding $30 billion Device helps enable drug commercialization (avoids invasive surgery) Device-IP may extend lifecycle of combination products 24

25 Recent Capital Raising U.S. institutional investors purchased 8.25 million shares of Unilife common stock at a price of $4.35 per share 1 st U.S. offering over-subscribed, strong participation from bluechip accounts, healthcare dedicated and long-only funds 8.6% discount to UNIS s closing price of $ % of outstanding shares after this offering Net proceeds from offering are approximately $33.8 million 25

26 Recent Capital Raising Benefits of stronger cash position and balance sheet include: Strengthens negotiating position as Unilife begins to finalize partnership agreements with pharmaceutical companies Acceleration of R&D pipeline Expand workforce to support continued business growth Broadens and expands Unilife shareholder base 26

27 Summary All key elements of business strategy now in place Commercial rollout of Unifill proceeding exactly to plan Developed significant new pipeline products in direct response to unmet customer needs Discussions with multiple customers across multiple areas Attractive model with long-term contracts and strong margins Redefining the market for advanced drug delivery systems Differentiated products aimed at fastest-growing, highest-value sectors Becoming intertwined with $200 billion global injectable drug market 27

28 Resolutions 28

29 Item 1. Election of Directors For Withheld Item 1.1 Jim Bosnjak 23,743, % 2,666, % Item 1.2 Jeff Carter 25,166, % 1,243, % Item 1.3 William Galle 24,153, % 2,256, % Item 1.4 John Lund 24,610, % 1,799, % Item 1.5 Mary Kate Wold 26,056, % 353, % Item 1.6 Marc Firestone 26,055, % 354, % Item 1.7 Alan Shortall 24,496, % 914, % 29

30 Item 2. To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending June 30, 2012 Item 2. 32,098,125 (98.95%) For Against Abstain 216,238 (0.67%) 125,140 (0.38%) 30

31 Item 3. To consider and act on an advisory vote regarding the approval of compensation paid to certain executive officers Item 3. 22,188,789 (84.02%) For Against Abstain 3,535,099 (13.38%) 686,381 (2.60%) 31

32 Item 4. To consider and act on an advisory vote regarding the frequency of stockholder approval of the compensation of certain executive officers Item 4. 12,011,375 (47.90%) 1 Year 2 Years 3 Years 1,668,868 (6.65%) 11,396,460 (45.45%) 32

33 Item 5. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Slavko James Joseph Bosnjak on the terms set out in the proxy statement Item 5.* 16,105,195 (73.31%) For Against Abstain 5,537,395 (25.20%) 327,057 (1.49%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 33

34 Item 6. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Jeff Carter on the terms set out in the proxy statement Item 6.* 16,260,219 (74.01%) For Against Abstain 5,394,782 (24.56%) 314,646 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 34

35 Item 7. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to William Galle on the terms set out in the proxy statement Item 7.* 16,222,434 (73.84%) For Against Abstain 5,437,066 (24.75%) 310,147 (1.41%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 35

36 Item 8. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to John Lund on the terms set out in the proxy statement Item 8.* 16,314,099 (74.26%) For Against Abstain 5,341,901 (24.31%) 313,647 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 36

37 Item 9. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Mary Katherine Wold on the terms set out in the proxy statement Item 9.* 16,328,849 (74.33%) For Against Abstain 5,325,651 (24.24%) 315,147 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 37

38 Item 10. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 45,000 securities to Marc Firestone on the terms set out in the proxy statement Item 10.* 16,272,275 (74.07%) For Against Abstain 5,382,225 (24.50%) 315,147 (1.43%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 38

39 Item 11. For the purposes of ASX Listing Rule and for all other purposes, to approve the grant of up to 1,916,000 securities to Alan D. Shortall on the terms set out in the proxy statement Item 11.* 15,183,097 (69.11%) For Against Abstain 6,354,190 (28.92%) 432,360 (1.97%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 39

40 Item 12. For the purposes of ASX Listing Rule 7.2 (Exception 9) and for all other purposes, to approve the 2009 Stock Incentive Plan, as proposed to be amended Item 12.* 15,852,588 (72.16%) For Against Abstain 5,518,225 (25.12%) 598,834 (2.72%) * Excludes 4,440,622 shares voted on this proposal as required by ASX rules. 40

41 Questions 41

42 Other Business 42

43 Meeting Close 43